ConductScience.org, home

Paper7366733

Role of NK cells in tumour growth and metastasis in beige mice.

Talmadge JE and 3 others. Nature, 1980. Cited by 516 papers, by iCite.

Cite this record

ConductScience Library. Role of NK cells in tumour growth and metastasis in beige mice. Papers, record 7366733. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7366733

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Role of NK cells in tumour growth and metastasis in beige mice.
PubMed
Journal
Nature
PubMed
Year
1980
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
516
iCite
Relative citation ratio, by iCite
12.5
iCite
Revised in PubMed
2019-06-17
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Talmadge JEJ E
2Meyers KMK M
3Prieur DJD J
4Starkey JRJ R

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunity, CellularMajor topic
Immunity, InnateMajor topic
Killer Cells, NaturalMajor topic
MelanomaMajor topic
Mice, Mutant StrainsMajor topic
Animals
Lung Neoplasms
Mice
Models, Biological
Neoplasm Metastasis
Neoplasms, Experimental

Source PubMed

Download CSV of topics

Cited by133

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 516 citations.

PMIDTitleJournalYearIn PapersSource
41107895The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies.Cancer Cell Int2025https://conductscience.org/library/papers/41107895PubMed
38022613Modulation of natural killer cell exhaustion in the lungs: the key components from lung microenvironment and lung tumor microenvironment.Front Immunol2023https://conductscience.org/library/papers/38022613PubMed
37762486
Therapeutic Anti-KIR Antibody of 1-7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom.
Int J Mol Sci2023https://conductscience.org/library/papers/37762486PubMed
36844875The Efficacy and Hemorheological Indexes of Ginseng and Its Active Components for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.J Oncol2023https://conductscience.org/library/papers/36844875PubMed
35326467Aging of the Immune System: Focus on Natural Killer Cells Phenotype and Functions.Cells2022https://conductscience.org/library/papers/35326467PubMed
35325068Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.Clin Exp Immunol2022https://conductscience.org/library/papers/35325068PubMed
35110548Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells.Nat Commun2022https://conductscience.org/library/papers/35110548PubMed
35001010Immunoenhancing Effects of Euglena gracilis on a Cyclophosphamide-Induced Immunosuppressive Mouse Model.J Microbiol Biotechnol2022https://conductscience.org/library/papers/35001010PubMed
34788549Innate Immunity and Cancer Pathophysiology.Annu Rev Pathol2022https://conductscience.org/library/papers/34788549PubMed
34745769Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner.Oncoimmunology2021https://conductscience.org/library/papers/34745769PubMed
34576141Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.Int J Mol Sci2021https://conductscience.org/library/papers/34576141PubMed
34014424Myeloid derived suppressor cells and the release of micro-metastases from dormancy.Clin Exp Metastasis2021https://conductscience.org/library/papers/34014424PubMed
33546248Killing the Invaders: NK Cell Impact in Tumors and Anti-Tumor Therapy.Cancers (Basel)2021https://conductscience.org/library/papers/33546248PubMed
31662515Impact of Awake Breast Cancer Surgery on Postoperative Lymphocyte Responses.In Vivo2019https://conductscience.org/library/papers/31662515PubMed
31172847Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.MAbs2019https://conductscience.org/library/papers/31172847PubMed
30546365Ginsenoside F1 Promotes Cytotoxic Activity of NK Cells via Insulin-Like Growth Factor-1-Dependent Mechanism.Front Immunol2018https://conductscience.org/library/papers/30546365PubMed
29867983IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction.Front Immunol2018https://conductscience.org/library/papers/29867983PubMed
29456538An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells.Front Immunol2018https://conductscience.org/library/papers/29456538PubMed
29354116Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review.Front Immunol2017https://conductscience.org/library/papers/29354116PubMed
29031720Brown adipocytes can display a mammary basal myoepithelial cell phenotype in vivo.Mol Metab2017https://conductscience.org/library/papers/29031720PubMed

See all 133 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7366733

GET https://conductscience.org/api/papers/v1/7366733/cited_by?page=2